PF 06669571

Drug Profile

PF 06669571

Alternative Names: PF-06669571

Latest Information Update: 18 Jul 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class Antiparkinsonians
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cognition disorders; Parkinson's disease

Most Recent Events

  • 31 May 2016 Pfizer completes a phase Ib trial for idiopathic Parkinson's disease in USA (NCT02565628)
  • 01 Nov 2015 Phase-Ib clinical trials in Parkinson's disease in USA (PO) (NCT02565628)
  • 28 Sep 2015 Pfizer plans a phase Ib trial for idiopathic Parkinson's disease in USA (NCT02565628)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top